| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 111 | 2024 | 145 | 40.670 |
Why?
|
| Arthroplasty, Replacement, Knee | 58 | 2023 | 133 | 22.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 52 | 2024 | 101 | 21.020 |
Why?
|
| Arthritis, Rheumatoid | 70 | 2024 | 456 | 18.650 |
Why?
|
| Antirheumatic Agents | 58 | 2024 | 227 | 17.130 |
Why?
|
| Rheumatology | 59 | 2024 | 137 | 14.360 |
Why?
|
| Gout Suppressants | 49 | 2021 | 73 | 13.640 |
Why?
|
| Allopurinol | 34 | 2020 | 87 | 12.380 |
Why?
|
| Osteoarthritis | 25 | 2023 | 115 | 10.410 |
Why?
|
| Osteoarthritis, Knee | 31 | 2023 | 196 | 9.500 |
Why?
|
| Medicare | 36 | 2021 | 934 | 8.720 |
Why?
|
| Osteoarthritis, Hip | 22 | 2023 | 40 | 8.610 |
Why?
|
| Uric Acid | 34 | 2024 | 128 | 7.600 |
Why?
|
| Rheumatic Diseases | 33 | 2023 | 101 | 7.450 |
Why?
|
| Biological Products | 25 | 2024 | 316 | 6.830 |
Why?
|
| Febuxostat | 17 | 2021 | 21 | 6.280 |
Why?
|
| Hospitalization | 30 | 2022 | 2206 | 5.720 |
Why?
|
| Arthroplasty, Replacement | 13 | 2023 | 38 | 5.430 |
Why?
|
| Hyperuricemia | 12 | 2022 | 49 | 5.260 |
Why?
|
| Patient Participation | 17 | 2024 | 451 | 5.190 |
Why?
|
| Patient Acceptance of Health Care | 16 | 2023 | 606 | 5.190 |
Why?
|
| Lupus Erythematosus, Systemic | 10 | 2024 | 271 | 4.820 |
Why?
|
| United States | 109 | 2024 | 15998 | 4.370 |
Why?
|
| Length of Stay | 28 | 2024 | 2017 | 3.890 |
Why?
|
| Lupus Nephritis | 7 | 2019 | 62 | 3.760 |
Why?
|
| Comorbidity | 41 | 2021 | 2430 | 3.750 |
Why?
|
| Humans | 434 | 2024 | 271144 | 3.640 |
Why?
|
| Hospital Mortality | 21 | 2024 | 1315 | 3.480 |
Why?
|
| Knee Joint | 11 | 2022 | 168 | 3.240 |
Why?
|
| Aged | 162 | 2024 | 73178 | 3.160 |
Why?
|
| Shoulder Joint | 8 | 2015 | 62 | 3.120 |
Why?
|
| Quality of Life | 47 | 2023 | 4725 | 3.090 |
Why?
|
| Immunosuppressive Agents | 10 | 2021 | 1456 | 3.070 |
Why?
|
| Male | 210 | 2024 | 128590 | 2.990 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2023 | 72 | 2.980 |
Why?
|
| Reoperation | 22 | 2020 | 1390 | 2.910 |
Why?
|
| Randomized Controlled Trials as Topic | 37 | 2024 | 2670 | 2.890 |
Why?
|
| Postoperative Complications | 24 | 2024 | 5691 | 2.850 |
Why?
|
| Veterans | 17 | 2022 | 1764 | 2.830 |
Why?
|
| Female | 217 | 2024 | 148642 | 2.820 |
Why?
|
| Pain Measurement | 31 | 2021 | 1011 | 2.640 |
Why?
|
| Substance-Related Disorders | 5 | 2021 | 553 | 2.630 |
Why?
|
| Risk Factors | 70 | 2021 | 17838 | 2.630 |
Why?
|
| Aged, 80 and over | 83 | 2024 | 30937 | 2.580 |
Why?
|
| Middle Aged | 152 | 2024 | 90072 | 2.550 |
Why?
|
| Hospital Charges | 10 | 2024 | 88 | 2.510 |
Why?
|
| Cohort Studies | 45 | 2020 | 9436 | 2.380 |
Why?
|
| Pain, Postoperative | 9 | 2023 | 654 | 2.350 |
Why?
|
| Clinical Trials as Topic | 31 | 2023 | 3868 | 2.300 |
Why?
|
| Pain | 19 | 2023 | 1692 | 2.250 |
Why?
|
| Treatment Outcome | 97 | 2024 | 33842 | 2.220 |
Why?
|
| Vasculitis | 3 | 2021 | 78 | 2.190 |
Why?
|
| Incidence | 37 | 2021 | 5846 | 2.150 |
Why?
|
| Methotrexate | 13 | 2022 | 1027 | 2.080 |
Why?
|
| Registries | 15 | 2024 | 2231 | 2.070 |
Why?
|
| Arthritis, Psoriatic | 9 | 2022 | 23 | 2.030 |
Why?
|
| Cocaine | 3 | 2021 | 245 | 2.010 |
Why?
|
| Decision Support Techniques | 5 | 2024 | 609 | 2.010 |
Why?
|
| Scleroderma, Systemic | 4 | 2020 | 161 | 1.960 |
Why?
|
| Sjogren's Syndrome | 3 | 2020 | 104 | 1.910 |
Why?
|
| Hip Joint | 5 | 2016 | 56 | 1.890 |
Why?
|
| Practice Guidelines as Topic | 20 | 2020 | 2426 | 1.860 |
Why?
|
| Pyrroles | 7 | 2018 | 592 | 1.850 |
Why?
|
| Delivery of Health Care | 11 | 2022 | 871 | 1.850 |
Why?
|
| Communicable Diseases | 4 | 2021 | 210 | 1.820 |
Why?
|
| Activities of Daily Living | 11 | 2019 | 555 | 1.810 |
Why?
|
| Dementia | 5 | 2018 | 483 | 1.800 |
Why?
|
| Surgeons | 5 | 2023 | 484 | 1.760 |
Why?
|
| Glucocorticoids | 7 | 2021 | 628 | 1.750 |
Why?
|
| Self Report | 8 | 2021 | 792 | 1.740 |
Why?
|
| Recovery of Function | 14 | 2017 | 690 | 1.720 |
Why?
|
| Arthroplasty, Replacement, Ankle | 3 | 2019 | 3 | 1.720 |
Why?
|
| Periprosthetic Fractures | 4 | 2013 | 6 | 1.670 |
Why?
|
| Piperidines | 7 | 2018 | 1089 | 1.660 |
Why?
|
| Databases, Factual | 17 | 2023 | 2290 | 1.650 |
Why?
|
| Qualitative Research | 6 | 2024 | 623 | 1.650 |
Why?
|
| Arthritis, Gouty | 3 | 2019 | 9 | 1.610 |
Why?
|
| Humeral Head | 4 | 2011 | 5 | 1.610 |
Why?
|
| Telemedicine | 4 | 2022 | 547 | 1.580 |
Why?
|
| Low Back Pain | 3 | 2022 | 86 | 1.580 |
Why?
|
| Cardiovascular Diseases | 9 | 2023 | 2282 | 1.570 |
Why?
|
| Fibromyalgia | 2 | 2022 | 14 | 1.550 |
Why?
|
| Hypertension | 10 | 2022 | 1620 | 1.510 |
Why?
|
| Arthritis | 5 | 2017 | 149 | 1.480 |
Why?
|
| Medicaid | 6 | 2021 | 309 | 1.470 |
Why?
|
| Physician-Patient Relations | 5 | 2022 | 742 | 1.470 |
Why?
|
| United States Department of Veterans Affairs | 9 | 2021 | 672 | 1.460 |
Why?
|
| Surveys and Questionnaires | 31 | 2022 | 5902 | 1.440 |
Why?
|
| Health Status | 14 | 2016 | 626 | 1.440 |
Why?
|
| Hallucinogens | 2 | 2021 | 47 | 1.430 |
Why?
|
| Anti-Anxiety Agents | 2 | 2021 | 99 | 1.430 |
Why?
|
| Shoulder Pain | 4 | 2011 | 35 | 1.420 |
Why?
|
| Cannabis | 2 | 2021 | 69 | 1.410 |
Why?
|
| Prosthesis-Related Infections | 4 | 2019 | 228 | 1.380 |
Why?
|
| Severity of Illness Index | 27 | 2021 | 4394 | 1.380 |
Why?
|
| Disease Management | 7 | 2020 | 1112 | 1.380 |
Why?
|
| Chondrocalcinosis | 7 | 2021 | 26 | 1.350 |
Why?
|
| Spondylarthritis | 3 | 2020 | 12 | 1.340 |
Why?
|
| Sex Factors | 18 | 2020 | 2193 | 1.330 |
Why?
|
| Emergency Service, Hospital | 5 | 2018 | 1240 | 1.330 |
Why?
|
| Hypothyroidism | 2 | 2023 | 211 | 1.320 |
Why?
|
| Diabetes Mellitus | 10 | 2024 | 1079 | 1.310 |
Why?
|
| Antibodies, Monoclonal | 15 | 2020 | 4511 | 1.290 |
Why?
|
| Giant Cell Arteritis | 2 | 2020 | 64 | 1.230 |
Why?
|
| Patient Satisfaction | 9 | 2019 | 916 | 1.220 |
Why?
|
| Chronic Pain | 7 | 2021 | 262 | 1.220 |
Why?
|
| Age Factors | 21 | 2020 | 5497 | 1.220 |
Why?
|
| Arthralgia | 6 | 2021 | 97 | 1.220 |
Why?
|
| Time Factors | 27 | 2021 | 13131 | 1.210 |
Why?
|
| Proportional Hazards Models | 17 | 2020 | 5088 | 1.210 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 751 | 1.210 |
Why?
|
| Risk Assessment | 20 | 2023 | 6838 | 1.210 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2016 | 567 | 1.210 |
Why?
|
| Healthcare Disparities | 6 | 2018 | 647 | 1.200 |
Why?
|
| Osteonecrosis | 3 | 2023 | 55 | 1.200 |
Why?
|
| Spondylitis, Ankylosing | 6 | 2017 | 29 | 1.190 |
Why?
|
| Income | 3 | 2023 | 228 | 1.180 |
Why?
|
| Alcoholism | 2 | 2021 | 329 | 1.180 |
Why?
|
| Decision Making | 11 | 2019 | 1245 | 1.180 |
Why?
|
| Cross-Sectional Studies | 19 | 2022 | 4510 | 1.170 |
Why?
|
| Plant Extracts | 3 | 2020 | 226 | 1.160 |
Why?
|
| Inpatients | 6 | 2021 | 692 | 1.150 |
Why?
|
| Medication Adherence | 6 | 2019 | 519 | 1.150 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 417 | 1.140 |
Why?
|
| Urinary Tract Infections | 3 | 2021 | 344 | 1.140 |
Why?
|
| Arthritis, Infectious | 2 | 2018 | 74 | 1.140 |
Why?
|
| Disability Evaluation | 8 | 2014 | 243 | 1.130 |
Why?
|
| Adult | 67 | 2024 | 81619 | 1.120 |
Why?
|
| Logistic Models | 14 | 2021 | 3437 | 1.110 |
Why?
|
| Etanercept | 10 | 2020 | 70 | 1.100 |
Why?
|
| Sleep | 3 | 2019 | 437 | 1.090 |
Why?
|
| Evidence-Based Medicine | 13 | 2018 | 1062 | 1.080 |
Why?
|
| Orthopedic Surgeons | 4 | 2020 | 13 | 1.080 |
Why?
|
| Multivariate Analysis | 13 | 2020 | 4332 | 1.070 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 1303 | 1.070 |
Why?
|
| Health Surveys | 8 | 2019 | 406 | 1.040 |
Why?
|
| Arthritis, Juvenile | 4 | 2024 | 59 | 1.030 |
Why?
|
| Prospective Studies | 26 | 2023 | 13354 | 1.030 |
Why?
|
| Network Meta-Analysis | 5 | 2023 | 53 | 1.030 |
Why?
|
| Blood Transfusion | 4 | 2024 | 581 | 1.030 |
Why?
|
| Consensus | 20 | 2024 | 1106 | 1.020 |
Why?
|
| Pyrimidines | 7 | 2018 | 3667 | 1.020 |
Why?
|
| Retrospective Studies | 38 | 2024 | 39722 | 1.010 |
Why?
|
| Arthroplasty, Replacement, Elbow | 2 | 2015 | 3 | 1.000 |
Why?
|
| Sleep Wake Disorders | 2 | 2019 | 363 | 1.000 |
Why?
|
| Sepsis | 2 | 2021 | 689 | 0.990 |
Why?
|
| Rheumatologists | 2 | 2021 | 10 | 0.950 |
Why?
|
| Health Services | 4 | 2019 | 102 | 0.950 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 536 | 0.920 |
Why?
|
| Surgical Wound Infection | 4 | 2017 | 470 | 0.920 |
Why?
|
| Teratogens | 1 | 2024 | 92 | 0.910 |
Why?
|
| Global Health | 12 | 2023 | 693 | 0.910 |
Why?
|
| Primary Health Care | 5 | 2022 | 844 | 0.910 |
Why?
|
| Odds Ratio | 11 | 2019 | 2288 | 0.900 |
Why?
|
| Diabetes Complications | 2 | 2017 | 317 | 0.890 |
Why?
|
| Cerebrovascular Disorders | 3 | 2015 | 162 | 0.890 |
Why?
|
| Drug Therapy, Combination | 10 | 2022 | 2373 | 0.870 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2020 | 547 | 0.870 |
Why?
|
| Abatacept | 8 | 2019 | 43 | 0.860 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 2 | 2020 | 7 | 0.860 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 25 | 0.830 |
Why?
|
| Uveitis | 2 | 2022 | 38 | 0.830 |
Why?
|
| Genetic Loci | 2 | 2022 | 464 | 0.830 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2022 | 17 | 0.830 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 238 | 0.830 |
Why?
|
| Public Health | 4 | 2020 | 298 | 0.820 |
Why?
|
| Musculoskeletal Diseases | 6 | 2023 | 95 | 0.820 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 75 | 0.820 |
Why?
|
| Rectal Fistula | 1 | 2022 | 7 | 0.810 |
Why?
|
| Hemiarthroplasty | 2 | 2011 | 4 | 0.810 |
Why?
|
| Gracilis Muscle | 1 | 2022 | 7 | 0.810 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 171 | 0.810 |
Why?
|
| Penile Implantation | 1 | 2022 | 27 | 0.810 |
Why?
|
| Penile Prosthesis | 1 | 2022 | 41 | 0.800 |
Why?
|
| Stroke | 5 | 2019 | 1092 | 0.790 |
Why?
|
| Urinary Fistula | 1 | 2022 | 34 | 0.790 |
Why?
|
| Health Services Accessibility | 5 | 2019 | 806 | 0.790 |
Why?
|
| Urethral Diseases | 1 | 2022 | 39 | 0.790 |
Why?
|
| Urinary Bladder Diseases | 1 | 2022 | 55 | 0.790 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2019 | 1618 | 0.780 |
Why?
|
| Ureter | 1 | 2023 | 229 | 0.770 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2015 | 217 | 0.770 |
Why?
|
| Health Equity | 6 | 2017 | 58 | 0.770 |
Why?
|
| Botulinum Toxins | 4 | 2012 | 136 | 0.760 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 5 | 2016 | 105 | 0.760 |
Why?
|
| Infliximab | 8 | 2018 | 139 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 3398 | 0.760 |
Why?
|
| Automobile Driving | 1 | 2021 | 32 | 0.750 |
Why?
|
| Obesity | 6 | 2024 | 2941 | 0.750 |
Why?
|
| Knee Prosthesis | 2 | 2011 | 11 | 0.750 |
Why?
|
| Colchicine | 2 | 2020 | 72 | 0.750 |
Why?
|
| Hearing Loss | 2 | 2023 | 173 | 0.740 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 41 | 0.740 |
Why?
|
| Body Mass Index | 5 | 2024 | 2238 | 0.740 |
Why?
|
| Drug Monitoring | 3 | 2020 | 356 | 0.740 |
Why?
|
| Global Burden of Disease | 5 | 2023 | 28 | 0.730 |
Why?
|
| Kidney Diseases | 2 | 2017 | 748 | 0.730 |
Why?
|
| Prunus domestica | 1 | 2020 | 1 | 0.730 |
Why?
|
| Analgesics | 4 | 2021 | 408 | 0.730 |
Why?
|
| Cannabidiol | 1 | 2021 | 43 | 0.730 |
Why?
|
| Diagnostic Techniques and Procedures | 3 | 2019 | 51 | 0.730 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 789 | 0.730 |
Why?
|
| Diet Therapy | 2 | 2020 | 53 | 0.730 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2020 | 5 | 0.730 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 67 | 0.720 |
Why?
|
| Freedom | 1 | 2020 | 19 | 0.720 |
Why?
|
| Hospitals, Veterans | 4 | 2019 | 380 | 0.710 |
Why?
|
| Dissent and Disputes | 1 | 2020 | 40 | 0.710 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 31 | 0.710 |
Why?
|
| Polymyositis | 1 | 2020 | 10 | 0.710 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 749 | 0.710 |
Why?
|
| Range of Motion, Articular | 4 | 2017 | 112 | 0.700 |
Why?
|
| Adalimumab | 7 | 2022 | 47 | 0.700 |
Why?
|
| Follow-Up Studies | 16 | 2022 | 15260 | 0.700 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 291 | 0.690 |
Why?
|
| Finches | 1 | 2019 | 6 | 0.690 |
Why?
|
| Dyslipidemias | 1 | 2022 | 244 | 0.690 |
Why?
|
| Minnesota | 7 | 2016 | 126 | 0.680 |
Why?
|
| Social Perception | 1 | 2020 | 75 | 0.680 |
Why?
|
| Tai Ji | 1 | 2019 | 16 | 0.680 |
Why?
|
| Knee Injuries | 1 | 2019 | 54 | 0.680 |
Why?
|
| Erectile Dysfunction | 1 | 2022 | 248 | 0.670 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2024 | 1228 | 0.670 |
Why?
|
| Elective Surgical Procedures | 5 | 2017 | 247 | 0.670 |
Why?
|
| Cost of Illness | 4 | 2017 | 504 | 0.660 |
Why?
|
| Immunoconjugates | 4 | 2010 | 315 | 0.660 |
Why?
|
| Hospitals, County | 1 | 2019 | 31 | 0.660 |
Why?
|
| Prostatectomy | 1 | 2024 | 1005 | 0.660 |
Why?
|
| Wounds and Injuries | 6 | 2020 | 443 | 0.660 |
Why?
|
| Advisory Committees | 1 | 2020 | 210 | 0.650 |
Why?
|
| Physicians | 3 | 2022 | 872 | 0.650 |
Why?
|
| Prosthesis Failure | 4 | 2013 | 201 | 0.650 |
Why?
|
| Phytotherapy | 2 | 2020 | 113 | 0.650 |
Why?
|
| Immunologic Factors | 3 | 2012 | 671 | 0.650 |
Why?
|
| Myositis | 2 | 2022 | 86 | 0.650 |
Why?
|
| Patient Discharge | 6 | 2020 | 708 | 0.640 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 50 | 0.640 |
Why?
|
| Endometriosis | 1 | 2022 | 235 | 0.640 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2023 | 851 | 0.640 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2010 | 180 | 0.640 |
Why?
|
| Cocaine-Related Disorders | 1 | 2021 | 239 | 0.630 |
Why?
|
| Speech | 1 | 2020 | 139 | 0.630 |
Why?
|
| Vulnerable Populations | 5 | 2017 | 185 | 0.630 |
Why?
|
| Drug Hypersensitivity | 1 | 2020 | 134 | 0.630 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2019 | 97 | 0.630 |
Why?
|
| Pandemics | 5 | 2022 | 1597 | 0.630 |
Why?
|
| Population Surveillance | 2 | 2019 | 649 | 0.630 |
Why?
|
| Symptom Flare Up | 6 | 2021 | 29 | 0.630 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 91 | 0.620 |
Why?
|
| Coronary Disease | 4 | 2021 | 774 | 0.620 |
Why?
|
| Ultrasonography | 3 | 2021 | 1934 | 0.620 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 323 | 0.620 |
Why?
|
| Patient Readmission | 4 | 2017 | 591 | 0.610 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2016 | 1050 | 0.610 |
Why?
|
| Quality-Adjusted Life Years | 10 | 2023 | 235 | 0.600 |
Why?
|
| Health Status Indicators | 4 | 2019 | 235 | 0.590 |
Why?
|
| Forecasting | 5 | 2013 | 707 | 0.580 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 528 | 0.580 |
Why?
|
| Sacroiliac Joint | 1 | 2017 | 19 | 0.570 |
Why?
|
| Research Design | 16 | 2021 | 1568 | 0.570 |
Why?
|
| Spiro Compounds | 1 | 2017 | 59 | 0.570 |
Why?
|
| Attitude to Health | 2 | 2020 | 438 | 0.570 |
Why?
|
| Thiazoles | 2 | 2012 | 729 | 0.560 |
Why?
|
| Furans | 1 | 2017 | 103 | 0.560 |
Why?
|
| Back Pain | 1 | 2017 | 63 | 0.560 |
Why?
|
| Substance P | 1 | 2017 | 75 | 0.560 |
Why?
|
| Pneumonia | 3 | 2021 | 796 | 0.560 |
Why?
|
| Macular Degeneration | 1 | 2018 | 122 | 0.560 |
Why?
|
| Patient Preference | 3 | 2020 | 222 | 0.550 |
Why?
|
| Sickness Impact Profile | 3 | 2011 | 137 | 0.550 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 247 | 0.550 |
Why?
|
| Urate Oxidase | 3 | 2012 | 43 | 0.550 |
Why?
|
| Uricosuric Agents | 2 | 2020 | 5 | 0.540 |
Why?
|
| Chronic Disease | 14 | 2015 | 1859 | 0.540 |
Why?
|
| Physical Fitness | 3 | 2016 | 125 | 0.540 |
Why?
|
| Health Resources | 1 | 2018 | 173 | 0.540 |
Why?
|
| Research | 3 | 2014 | 428 | 0.540 |
Why?
|
| Fees and Charges | 1 | 2016 | 14 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 267 | 0.530 |
Why?
|
| Review Literature as Topic | 5 | 2017 | 83 | 0.530 |
Why?
|
| Prosthesis Design | 3 | 2022 | 662 | 0.530 |
Why?
|
| Reproducibility of Results | 15 | 2021 | 6165 | 0.530 |
Why?
|
| Consumer Behavior | 1 | 2016 | 47 | 0.530 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2020 | 765 | 0.520 |
Why?
|
| Joint Prosthesis | 3 | 2011 | 16 | 0.520 |
Why?
|
| Self Care | 1 | 2017 | 242 | 0.520 |
Why?
|
| Prunus | 1 | 2015 | 1 | 0.520 |
Why?
|
| Chemokines | 1 | 2017 | 293 | 0.520 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2015 | 5 | 0.520 |
Why?
|
| Drug Substitution | 1 | 2015 | 86 | 0.520 |
Why?
|
| Inflammation | 5 | 2022 | 2526 | 0.510 |
Why?
|
| Tobacco Use | 1 | 2015 | 65 | 0.510 |
Why?
|
| Quadriceps Muscle | 1 | 2015 | 12 | 0.500 |
Why?
|
| Chondroitin Sulfates | 1 | 2015 | 20 | 0.500 |
Why?
|
| Congresses as Topic | 1 | 2017 | 297 | 0.500 |
Why?
|
| Biological Factors | 1 | 2015 | 49 | 0.500 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 53 | 0.490 |
Why?
|
| Ankle Joint | 1 | 2015 | 37 | 0.490 |
Why?
|
| Drug Therapy | 1 | 2015 | 208 | 0.490 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 148 | 0.480 |
Why?
|
| Complementary Therapies | 1 | 2016 | 125 | 0.480 |
Why?
|
| Tacrolimus | 1 | 2016 | 354 | 0.480 |
Why?
|
| Depressive Disorder | 1 | 2018 | 566 | 0.480 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 241 | 0.480 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 77 | 0.480 |
Why?
|
| Depression | 6 | 2018 | 1735 | 0.480 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 919 | 0.480 |
Why?
|
| International Classification of Diseases | 3 | 2015 | 95 | 0.470 |
Why?
|
| Dietary Supplements | 2 | 2016 | 570 | 0.470 |
Why?
|
| Peripheral Arterial Disease | 1 | 2018 | 267 | 0.470 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 130 | 0.460 |
Why?
|
| Synovitis | 2 | 2004 | 23 | 0.460 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 121 | 0.460 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 306 | 0.460 |
Why?
|
| Comparative Effectiveness Research | 4 | 2017 | 124 | 0.460 |
Why?
|
| Smoking | 3 | 2011 | 2425 | 0.460 |
Why?
|
| Arthroplasty | 3 | 2011 | 22 | 0.450 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 1318 | 0.450 |
Why?
|
| Brassica napus | 3 | 2012 | 4 | 0.450 |
Why?
|
| Health Care Costs | 3 | 2016 | 703 | 0.450 |
Why?
|
| Mortality | 3 | 2021 | 353 | 0.440 |
Why?
|
| Predictive Value of Tests | 9 | 2016 | 4985 | 0.440 |
Why?
|
| Hospital Costs | 3 | 2021 | 255 | 0.440 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 696 | 0.440 |
Why?
|
| Plant Proteins | 3 | 2013 | 133 | 0.440 |
Why?
|
| Prognosis | 14 | 2021 | 22467 | 0.440 |
Why?
|
| Calcinosis | 3 | 2021 | 433 | 0.440 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 504 | 0.430 |
Why?
|
| Placebos | 4 | 2021 | 446 | 0.430 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 57 | 0.430 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 641 | 0.430 |
Why?
|
| Radiography | 8 | 2018 | 1989 | 0.430 |
Why?
|
| Administrative Claims, Healthcare | 3 | 2017 | 14 | 0.420 |
Why?
|
| Rural Population | 1 | 2015 | 292 | 0.420 |
Why?
|
| Symptom Assessment | 3 | 2020 | 274 | 0.420 |
Why?
|
| Tuberculosis | 3 | 2017 | 617 | 0.410 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 631 | 0.410 |
Why?
|
| Delphi Technique | 6 | 2019 | 271 | 0.410 |
Why?
|
| Health Personnel | 4 | 2021 | 644 | 0.410 |
Why?
|
| Rituximab | 5 | 2017 | 1590 | 0.400 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 707 | 0.400 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 42 | 0.400 |
Why?
|
| Arabidopsis Proteins | 2 | 2013 | 52 | 0.400 |
Why?
|
| Parkinson Disease | 1 | 2019 | 693 | 0.400 |
Why?
|
| Weight Loss | 3 | 2024 | 637 | 0.400 |
Why?
|
| Exercise | 3 | 2021 | 1211 | 0.390 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 366 | 0.390 |
Why?
|
| Precision Medicine | 2 | 2017 | 1201 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2022 | 7785 | 0.390 |
Why?
|
| Prevalence | 10 | 2023 | 3423 | 0.390 |
Why?
|
| Thromboembolism | 2 | 2011 | 151 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 5113 | 0.390 |
Why?
|
| Arabidopsis | 2 | 2013 | 76 | 0.380 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 4956 | 0.380 |
Why?
|
| Biomarkers | 11 | 2022 | 5108 | 0.380 |
Why?
|
| Propensity Score | 3 | 2020 | 774 | 0.370 |
Why?
|
| Terminology as Topic | 2 | 2017 | 421 | 0.370 |
Why?
|
| Peptic Ulcer | 1 | 2011 | 160 | 0.370 |
Why?
|
| Photosynthesis | 2 | 2012 | 16 | 0.360 |
Why?
|
| Patients | 3 | 2022 | 247 | 0.360 |
Why?
|
| Exercise Therapy | 3 | 2023 | 290 | 0.360 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.360 |
Why?
|
| Young Adult | 12 | 2024 | 22071 | 0.350 |
Why?
|
| Age Distribution | 4 | 2021 | 732 | 0.350 |
Why?
|
| Health Status Disparities | 1 | 2013 | 306 | 0.350 |
Why?
|
| Self Disclosure | 1 | 2009 | 30 | 0.340 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 295 | 0.340 |
Why?
|
| Creatinine | 3 | 2023 | 559 | 0.340 |
Why?
|
| Light-Harvesting Protein Complexes | 1 | 2009 | 4 | 0.340 |
Why?
|
| Xanthine Oxidase | 2 | 2022 | 21 | 0.340 |
Why?
|
| Efficiency | 1 | 2010 | 93 | 0.340 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 32 | 0.340 |
Why?
|
| Triazoles | 3 | 2019 | 632 | 0.330 |
Why?
|
| Spondylarthropathies | 1 | 2009 | 5 | 0.330 |
Why?
|
| Databases as Topic | 1 | 2009 | 139 | 0.330 |
Why?
|
| Hypnotics and Sedatives | 2 | 2021 | 222 | 0.330 |
Why?
|
| Calcium Pyrophosphate | 4 | 2021 | 7 | 0.330 |
Why?
|
| Perioperative Care | 3 | 2017 | 445 | 0.330 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 132 | 0.330 |
Why?
|
| Sex Distribution | 3 | 2020 | 503 | 0.320 |
Why?
|
| Morbidity | 4 | 2020 | 403 | 0.320 |
Why?
|
| Sample Size | 1 | 2009 | 206 | 0.320 |
Why?
|
| Internet | 4 | 2019 | 698 | 0.320 |
Why?
|
| Remission Induction | 6 | 2021 | 3648 | 0.320 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 3241 | 0.320 |
Why?
|
| Premenopause | 1 | 2009 | 139 | 0.320 |
Why?
|
| Organizational Innovation | 2 | 2021 | 73 | 0.310 |
Why?
|
| Drug Delivery Systems | 3 | 2011 | 662 | 0.310 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 978 | 0.310 |
Why?
|
| Heart Diseases | 2 | 2011 | 737 | 0.310 |
Why?
|
| Treatment Failure | 3 | 2017 | 1433 | 0.300 |
Why?
|
| Hospitals | 1 | 2011 | 495 | 0.300 |
Why?
|
| Thioglycolates | 2 | 2017 | 9 | 0.300 |
Why?
|
| Staphylococcus aureus | 1 | 2011 | 565 | 0.300 |
Why?
|
| Endpoint Determination | 2 | 2018 | 182 | 0.290 |
Why?
|
| Child Mortality | 2 | 2019 | 23 | 0.290 |
Why?
|
| Cluster Analysis | 2 | 2022 | 1070 | 0.290 |
Why?
|
| Patient Acuity | 2 | 2017 | 76 | 0.290 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2007 | 75 | 0.290 |
Why?
|
| Fusarium | 1 | 2007 | 57 | 0.290 |
Why?
|
| Health Literacy | 3 | 2019 | 115 | 0.280 |
Why?
|
| Certolizumab Pegol | 2 | 2016 | 8 | 0.280 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 720 | 0.280 |
Why?
|
| Immunoglobulin G | 5 | 2015 | 1152 | 0.280 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 364 | 0.280 |
Why?
|
| Evidence-Based Practice | 5 | 2017 | 129 | 0.270 |
Why?
|
| Data Collection | 2 | 2022 | 622 | 0.270 |
Why?
|
| Diphtheria Toxoid | 1 | 2006 | 13 | 0.270 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 352 | 0.270 |
Why?
|
| Interleukin-17 | 2 | 2018 | 257 | 0.270 |
Why?
|
| Infant Mortality | 2 | 2019 | 175 | 0.270 |
Why?
|
| Neoplasms | 5 | 2023 | 15848 | 0.270 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 684 | 0.260 |
Why?
|
| Polyesters | 1 | 2006 | 64 | 0.260 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 5185 | 0.260 |
Why?
|
| Bone Density | 1 | 2009 | 469 | 0.260 |
Why?
|
| Quality of Health Care | 1 | 2010 | 627 | 0.260 |
Why?
|
| Freezing | 1 | 2005 | 61 | 0.260 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 5990 | 0.260 |
Why?
|
| Immunity, Mucosal | 1 | 2006 | 121 | 0.260 |
Why?
|
| Bone and Bones | 1 | 2009 | 615 | 0.250 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 1326 | 0.250 |
Why?
|
| Utilization Review | 2 | 2016 | 54 | 0.250 |
Why?
|
| Life Expectancy | 4 | 2020 | 129 | 0.250 |
Why?
|
| Meta-Analysis as Topic | 3 | 2017 | 257 | 0.250 |
Why?
|
| Standard of Care | 2 | 2017 | 274 | 0.250 |
Why?
|
| Administration, Oral | 3 | 2023 | 1621 | 0.250 |
Why?
|
| Insurance Claim Review | 2 | 2018 | 74 | 0.250 |
Why?
|
| Nanostructures | 1 | 2006 | 101 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 333 | 0.250 |
Why?
|
| Feasibility Studies | 5 | 2020 | 2347 | 0.250 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 1424 | 0.250 |
Why?
|
| Societies, Medical | 5 | 2021 | 1348 | 0.250 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2621 | 0.250 |
Why?
|
| Health Care Surveys | 2 | 2021 | 423 | 0.250 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 1913 | 0.240 |
Why?
|
| Transcription Factors | 3 | 2013 | 5494 | 0.240 |
Why?
|
| Regression Analysis | 2 | 2018 | 1568 | 0.240 |
Why?
|
| Early Diagnosis | 2 | 2017 | 315 | 0.240 |
Why?
|
| Bayes Theorem | 3 | 2021 | 1036 | 0.240 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2024 | 18 | 0.230 |
Why?
|
| Reference Values | 3 | 2015 | 1156 | 0.230 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 59 | 0.230 |
Why?
|
| Scaphoid Bone | 1 | 2003 | 3 | 0.230 |
Why?
|
| Metacarpus | 1 | 2003 | 7 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4327 | 0.230 |
Why?
|
| Hearing Aids | 1 | 2023 | 15 | 0.230 |
Why?
|
| Osteolysis, Essential | 1 | 2003 | 8 | 0.230 |
Why?
|
| Talus | 1 | 2003 | 12 | 0.230 |
Why?
|
| Contraception | 1 | 2024 | 63 | 0.230 |
Why?
|
| Public Opinion | 2 | 2021 | 77 | 0.230 |
Why?
|
| Patella | 1 | 2003 | 39 | 0.220 |
Why?
|
| Eczema | 1 | 2023 | 36 | 0.220 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 350 | 0.220 |
Why?
|
| Tinnitus | 1 | 2023 | 39 | 0.220 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 51 | 0.220 |
Why?
|
| Ileum | 1 | 2023 | 175 | 0.220 |
Why?
|
| Acclimatization | 2 | 2013 | 40 | 0.210 |
Why?
|
| Adolescent | 9 | 2024 | 32621 | 0.210 |
Why?
|
| Escherichia coli | 1 | 2009 | 1309 | 0.210 |
Why?
|
| Consensus Development Conferences as Topic | 4 | 2015 | 78 | 0.210 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 324 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 606 | 0.200 |
Why?
|
| United Kingdom | 1 | 2022 | 281 | 0.200 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2014 | 33 | 0.200 |
Why?
|
| Pain Management | 2 | 2019 | 716 | 0.200 |
Why?
|
| Vaccination | 2 | 2021 | 1148 | 0.200 |
Why?
|
| Postoperative Period | 2 | 2016 | 671 | 0.200 |
Why?
|
| Antigens | 2 | 2017 | 288 | 0.200 |
Why?
|
| Amphetamines | 1 | 2021 | 10 | 0.200 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 1257 | 0.200 |
Why?
|
| Overweight | 2 | 2017 | 484 | 0.200 |
Why?
|
| Anastomosis, Surgical | 1 | 2023 | 372 | 0.200 |
Why?
|
| Communication | 2 | 2019 | 859 | 0.200 |
Why?
|
| Drug Design | 2 | 2015 | 378 | 0.200 |
Why?
|
| Organizations | 1 | 2021 | 22 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 534 | 0.200 |
Why?
|
| Injections, Intra-Articular | 3 | 2010 | 37 | 0.200 |
Why?
|
| Adverse Outcome Pathways | 1 | 2021 | 2 | 0.190 |
Why?
|
| Volatilization | 1 | 2021 | 8 | 0.190 |
Why?
|
| Amphetamine | 1 | 2021 | 18 | 0.190 |
Why?
|
| Erythrocytes | 2 | 2017 | 359 | 0.190 |
Why?
|
| Occupational Stress | 1 | 2021 | 14 | 0.190 |
Why?
|
| Algorithms | 2 | 2012 | 3910 | 0.190 |
Why?
|
| Disease Progression | 5 | 2017 | 6897 | 0.190 |
Why?
|
| Urinary Bladder | 1 | 2024 | 600 | 0.190 |
Why?
|
| Observational Studies as Topic | 3 | 2020 | 148 | 0.190 |
Why?
|
| Dronabinol | 1 | 2021 | 41 | 0.190 |
Why?
|
| Attitude to Computers | 1 | 2021 | 78 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2024 | 319 | 0.190 |
Why?
|
| Disabled Persons | 2 | 2020 | 113 | 0.190 |
Why?
|
| Pilot Projects | 4 | 2017 | 2854 | 0.180 |
Why?
|
| Physical Therapists | 1 | 2020 | 6 | 0.180 |
Why?
|
| Rotator Cuff Tear Arthropathy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Synovial Fluid | 1 | 2020 | 27 | 0.180 |
Why?
|
| Capsules | 1 | 2020 | 54 | 0.180 |
Why?
|
| Government | 1 | 2020 | 18 | 0.180 |
Why?
|
| Organizational Culture | 1 | 2021 | 118 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2021 | 124 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 371 | 0.180 |
Why?
|
| Rotator Cuff | 1 | 2020 | 23 | 0.180 |
Why?
|
| South Africa | 1 | 2020 | 109 | 0.180 |
Why?
|
| Spleen | 2 | 2017 | 736 | 0.180 |
Why?
|
| Psychometrics | 4 | 2014 | 963 | 0.180 |
Why?
|
| Bias | 1 | 2021 | 207 | 0.180 |
Why?
|
| Exercise Movement Techniques | 1 | 2019 | 3 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 566 | 0.170 |
Why?
|
| Workload | 1 | 2021 | 198 | 0.170 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 23 | 0.170 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 255 | 0.170 |
Why?
|
| Fatigue | 3 | 2024 | 1274 | 0.170 |
Why?
|
| Midwestern United States | 2 | 2009 | 22 | 0.170 |
Why?
|
| Survival Rate | 4 | 2017 | 12523 | 0.170 |
Why?
|
| Goals | 2 | 2018 | 189 | 0.170 |
Why?
|
| Politics | 1 | 2020 | 73 | 0.170 |
Why?
|
| Smoking Cessation | 2 | 2018 | 755 | 0.170 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 337 | 0.170 |
Why?
|
| Arthritis, Reactive | 2 | 2009 | 13 | 0.170 |
Why?
|
| Linear Models | 2 | 2015 | 1093 | 0.170 |
Why?
|
| Los Angeles | 1 | 2019 | 34 | 0.170 |
Why?
|
| Pamphlets | 1 | 2019 | 33 | 0.170 |
Why?
|
| Ustekinumab | 1 | 2018 | 2 | 0.170 |
Why?
|
| Enthesopathy | 1 | 2018 | 3 | 0.170 |
Why?
|
| Spondylitis | 1 | 2018 | 8 | 0.170 |
Why?
|
| Crohn Disease | 1 | 2022 | 322 | 0.160 |
Why?
|
| Anxiety | 2 | 2018 | 1234 | 0.160 |
Why?
|
| Patient Advocacy | 1 | 2019 | 89 | 0.160 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2019 | 64 | 0.160 |
Why?
|
| Interleukin-23 | 1 | 2018 | 29 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2015 | 1150 | 0.160 |
Why?
|
| International Cooperation | 2 | 2018 | 325 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 222 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 2474 | 0.160 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 2049 | 0.160 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 125 | 0.160 |
Why?
|
| Nurses | 1 | 2019 | 85 | 0.160 |
Why?
|
| Hospitals, Community | 1 | 2019 | 81 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 425 | 0.160 |
Why?
|
| Occupational Therapy | 1 | 2018 | 48 | 0.160 |
Why?
|
| Analysis of Variance | 2 | 2013 | 2316 | 0.160 |
Why?
|
| Azetidines | 1 | 2018 | 86 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 118 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 152 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 320 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 291 | 0.150 |
Why?
|
| Learning | 1 | 2021 | 430 | 0.150 |
Why?
|
| Choice Behavior | 1 | 2019 | 207 | 0.150 |
Why?
|
| Social Participation | 2 | 2016 | 26 | 0.150 |
Why?
|
| Interleukin-12 | 1 | 2018 | 267 | 0.140 |
Why?
|
| Diclofenac | 1 | 2017 | 11 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 90 | 0.140 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 60 | 0.140 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2017 | 109 | 0.140 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 44 | 0.140 |
Why?
|
| Macrophages, Peritoneal | 1 | 2017 | 76 | 0.140 |
Why?
|
| Free Radical Scavengers | 1 | 2017 | 84 | 0.140 |
Why?
|
| Neck Pain | 1 | 2017 | 41 | 0.140 |
Why?
|
| Manitoba | 1 | 2016 | 5 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6027 | 0.140 |
Why?
|
| Cytokines | 2 | 2017 | 2838 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 279 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2021 | 1600 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2009 | 881 | 0.140 |
Why?
|
| Acute Disease | 4 | 2017 | 2522 | 0.140 |
Why?
|
| Sheep | 1 | 2017 | 277 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3543 | 0.140 |
Why?
|
| Leadership | 1 | 2019 | 261 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2017 | 200 | 0.140 |
Why?
|
| Risk | 2 | 2018 | 1915 | 0.140 |
Why?
|
| Checklist | 1 | 2017 | 128 | 0.130 |
Why?
|
| Skin Transplantation | 1 | 2017 | 185 | 0.130 |
Why?
|
| Cold Temperature | 2 | 2013 | 130 | 0.130 |
Why?
|
| Cyclosporine | 1 | 2017 | 296 | 0.130 |
Why?
|
| Protective Factors | 1 | 2016 | 108 | 0.130 |
Why?
|
| Insurance, Health | 1 | 2018 | 263 | 0.130 |
Why?
|
| Rifampin | 1 | 2017 | 220 | 0.130 |
Why?
|
| Health Transition | 1 | 2015 | 11 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2021 | 826 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 5439 | 0.130 |
Why?
|
| Organic Anion Transporters | 1 | 2015 | 22 | 0.130 |
Why?
|
| Massachusetts | 1 | 2015 | 144 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 970 | 0.130 |
Why?
|
| Policy Making | 1 | 2015 | 78 | 0.130 |
Why?
|
| TWEAK Receptor | 1 | 2015 | 4 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 255 | 0.130 |
Why?
|
| Asthma | 1 | 2023 | 892 | 0.130 |
Why?
|
| Glucosamine | 1 | 2015 | 29 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2016 | 349 | 0.130 |
Why?
|
| Arkansas | 1 | 2015 | 60 | 0.130 |
Why?
|
| Managed Care Programs | 1 | 2015 | 84 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 520 | 0.120 |
Why?
|
| Life Style | 1 | 2018 | 615 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 408 | 0.120 |
Why?
|
| Skin | 1 | 2020 | 1290 | 0.120 |
Why?
|
| Perception | 1 | 2016 | 351 | 0.120 |
Why?
|
| Occupational Diseases | 1 | 2015 | 131 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2015 | 219 | 0.120 |
Why?
|
| Writing | 1 | 2015 | 104 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 1667 | 0.120 |
Why?
|
| Acculturation | 1 | 2015 | 111 | 0.120 |
Why?
|
| Happiness | 1 | 2014 | 10 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2019 | 607 | 0.120 |
Why?
|
| Botrytis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Oxylipins | 1 | 2013 | 4 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2021 | 1044 | 0.120 |
Why?
|
| Mediterranean Region | 3 | 2018 | 6 | 0.110 |
Why?
|
| Software | 2 | 2019 | 1361 | 0.110 |
Why?
|
| Hand | 1 | 2015 | 175 | 0.110 |
Why?
|
| Mobility Limitation | 1 | 2013 | 31 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 139 | 0.110 |
Why?
|
| Maternal Mortality | 1 | 2014 | 72 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 371 | 0.110 |
Why?
|
| Phytochrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| Plant Growth Regulators | 1 | 2013 | 14 | 0.110 |
Why?
|
| Chloroplasts | 1 | 2013 | 12 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2017 | 1369 | 0.110 |
Why?
|
| Cyclopentanes | 1 | 2013 | 44 | 0.110 |
Why?
|
| Hip Prosthesis | 1 | 2013 | 32 | 0.110 |
Why?
|
| Drug Costs | 2 | 2011 | 142 | 0.110 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 296 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 285 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 936 | 0.110 |
Why?
|
| Diet | 1 | 2021 | 1489 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 251 | 0.110 |
Why?
|
| Absorptiometry, Photon | 2 | 2015 | 237 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 238 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 1457 | 0.110 |
Why?
|
| Educational Measurement | 1 | 2016 | 400 | 0.110 |
Why?
|
| Illness Behavior | 1 | 2013 | 30 | 0.110 |
Why?
|
| Motivation | 1 | 2016 | 509 | 0.100 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 13 | 0.100 |
Why?
|
| Cementation | 1 | 2012 | 10 | 0.100 |
Why?
|
| Gene Frequency | 1 | 2015 | 1187 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2017 | 884 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 489 | 0.100 |
Why?
|
| Secondary Prevention | 2 | 2011 | 322 | 0.100 |
Why?
|
| Affect | 1 | 2014 | 303 | 0.100 |
Why?
|
| Organizational Objectives | 3 | 2019 | 68 | 0.100 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 97 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2013 | 136 | 0.100 |
Why?
|
| Pyridines | 1 | 2019 | 1312 | 0.100 |
Why?
|
| HIV Infections | 2 | 2022 | 2164 | 0.100 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2012 | 62 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2011 | 406 | 0.100 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 94 | 0.100 |
Why?
|
| Alabama | 1 | 2011 | 47 | 0.100 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 70 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 917 | 0.100 |
Why?
|
| Economics, Hospital | 1 | 2011 | 12 | 0.100 |
Why?
|
| Pennsylvania | 1 | 2011 | 66 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2015 | 1080 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2017 | 549 | 0.100 |
Why?
|
| Neglected Diseases | 1 | 2014 | 147 | 0.100 |
Why?
|
| Education, Medical | 1 | 2016 | 348 | 0.100 |
Why?
|
| Animals | 7 | 2019 | 62874 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 264 | 0.100 |
Why?
|
| Human Rights | 1 | 2011 | 25 | 0.100 |
Why?
|
| National Health Programs | 1 | 2011 | 41 | 0.100 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 339 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 129 | 0.090 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 43 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2013 | 265 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 1426 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1404 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2010 | 29 | 0.090 |
Why?
|
| Canada | 1 | 2012 | 432 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 85 | 0.090 |
Why?
|
| Urban Health | 1 | 2010 | 84 | 0.090 |
Why?
|
| Military Medicine | 1 | 2010 | 54 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 335 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 252 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 374 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 1554 | 0.090 |
Why?
|
| MEDLINE | 1 | 2009 | 35 | 0.090 |
Why?
|
| Polyethylene | 1 | 2009 | 22 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2018 | 1542 | 0.090 |
Why?
|
| Databases, Bibliographic | 1 | 2009 | 25 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 171 | 0.080 |
Why?
|
| Device Removal | 1 | 2012 | 337 | 0.080 |
Why?
|
| Caregivers | 3 | 2021 | 729 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 244 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 460 | 0.080 |
Why?
|
| Arthritis, Experimental | 1 | 2009 | 39 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2018 | 1922 | 0.080 |
Why?
|
| Polyglycolic Acid | 2 | 2006 | 38 | 0.080 |
Why?
|
| Solubility | 1 | 2009 | 251 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 53 | 0.080 |
Why?
|
| Developing Countries | 1 | 2011 | 339 | 0.080 |
Why?
|
| Particle Size | 2 | 2006 | 187 | 0.080 |
Why?
|
| Heart Failure | 2 | 2020 | 2498 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 198 | 0.080 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 40 | 0.080 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 103 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2009 | 104 | 0.080 |
Why?
|
| Quality Control | 1 | 2009 | 466 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 786 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 691 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 360 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2016 | 1326 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 269 | 0.070 |
Why?
|
| Regulon | 1 | 2007 | 16 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2019 | 1433 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 592 | 0.070 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2007 | 51 | 0.070 |
Why?
|
| Polymers | 2 | 2006 | 223 | 0.070 |
Why?
|
| Health Services Research | 1 | 2009 | 243 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2007 | 64 | 0.070 |
Why?
|
| Lactic Acid | 2 | 2006 | 312 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 475 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 686 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 1181 | 0.070 |
Why?
|
| Medication Errors | 1 | 2009 | 197 | 0.070 |
Why?
|
| Americas | 1 | 2006 | 56 | 0.070 |
Why?
|
| Mental Health Services | 1 | 2009 | 257 | 0.070 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 30 | 0.070 |
Why?
|
| Societies, Scientific | 1 | 2006 | 69 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 9046 | 0.070 |
Why?
|
| Carbon Monoxide | 1 | 2006 | 67 | 0.070 |
Why?
|
| Energy Intake | 1 | 2009 | 525 | 0.070 |
Why?
|
| Static Electricity | 1 | 2006 | 62 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 76 | 0.070 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2006 | 87 | 0.070 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 162 | 0.060 |
Why?
|
| Surface Properties | 1 | 2006 | 187 | 0.060 |
Why?
|
| Nasal Mucosa | 1 | 2006 | 76 | 0.060 |
Why?
|
| Body Composition | 1 | 2009 | 609 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2006 | 181 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2006 | 116 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 248 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2009 | 758 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2005 | 84 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2009 | 686 | 0.060 |
Why?
|
| Endocytosis | 1 | 2006 | 239 | 0.060 |
Why?
|
| Child | 4 | 2020 | 30462 | 0.060 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 52 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2004 | 47 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 532 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3929 | 0.060 |
Why?
|
| Phenotype | 1 | 2015 | 6467 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2004 | 111 | 0.060 |
Why?
|
| Diet, Reducing | 1 | 2024 | 85 | 0.060 |
Why?
|
| Recurrence | 1 | 2012 | 4887 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 4182 | 0.060 |
Why?
|
| Catastrophization | 1 | 2023 | 12 | 0.050 |
Why?
|
| Probability | 1 | 2005 | 875 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7951 | 0.050 |
Why?
|
| Drug Carriers | 1 | 2004 | 336 | 0.050 |
Why?
|
| Genes, Recessive | 1 | 2003 | 198 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2007 | 671 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 1509 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 142 | 0.050 |
Why?
|
| Immune System | 1 | 2004 | 276 | 0.050 |
Why?
|
| Patient Selection | 1 | 2010 | 2043 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2007 | 688 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 136 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 114 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2399 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2019 | 8608 | 0.050 |
Why?
|
| Siblings | 1 | 2003 | 299 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6251 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 317 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1184 | 0.050 |
Why?
|
| Diphosphates | 1 | 2021 | 14 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 237 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2006 | 1078 | 0.050 |
Why?
|
| Toxicity Tests | 1 | 2021 | 52 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 2490 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5325 | 0.050 |
Why?
|
| Translations | 1 | 2020 | 42 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 3655 | 0.050 |
Why?
|
| Muscles | 1 | 2022 | 462 | 0.050 |
Why?
|
| Germany | 1 | 2020 | 124 | 0.040 |
Why?
|
| Anemia | 1 | 2006 | 733 | 0.040 |
Why?
|
| Syndrome | 1 | 2003 | 1405 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 313 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 42 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10256 | 0.040 |
Why?
|
| United Nations | 1 | 2019 | 14 | 0.040 |
Why?
|
| Cause of Death | 2 | 2014 | 785 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 139 | 0.040 |
Why?
|
| Infant | 4 | 2019 | 13950 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2004 | 1274 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 251 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 3417 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 2674 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 746 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 239 | 0.040 |
Why?
|
| Base Sequence | 1 | 2005 | 5502 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2013 | 12207 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2006 | 2438 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2005 | 6494 | 0.040 |
Why?
|
| Organizational Case Studies | 1 | 2017 | 41 | 0.040 |
Why?
|
| Colombia | 1 | 2017 | 61 | 0.040 |
Why?
|
| Djibouti | 1 | 2017 | 2 | 0.040 |
Why?
|
| Somalia | 1 | 2017 | 4 | 0.040 |
Why?
|
| Africa, Northern | 1 | 2017 | 12 | 0.040 |
Why?
|
| Middle East | 1 | 2017 | 43 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2017 | 43 | 0.040 |
Why?
|
| Orthopedics | 1 | 2017 | 80 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1045 | 0.030 |
Why?
|
| Diuretics | 1 | 2017 | 198 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 435 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 516 | 0.030 |
Why?
|
| Pregnancy | 2 | 2022 | 8046 | 0.030 |
Why?
|
| Sanitation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mortality, Premature | 1 | 2015 | 11 | 0.030 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 123 | 0.030 |
Why?
|
| Knee | 1 | 2015 | 31 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 1312 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 1319 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2015 | 245 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2005 | 9312 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 276 | 0.030 |
Why?
|
| Metformin | 1 | 2017 | 395 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 5161 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 368 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 353 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 2083 | 0.030 |
Why?
|
| Plant Stomata | 1 | 2012 | 7 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 624 | 0.030 |
Why?
|
| Chlorophyll | 1 | 2012 | 17 | 0.030 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 10 | 0.030 |
Why?
|
| Plants, Genetically Modified | 1 | 2012 | 44 | 0.030 |
Why?
|
| Electron Transport | 1 | 2012 | 83 | 0.030 |
Why?
|
| Economics, Pharmaceutical | 1 | 2012 | 16 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2014 | 17011 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 2014 | 179 | 0.030 |
Why?
|
| Publishing | 1 | 2013 | 196 | 0.020 |
Why?
|
| Occupational Health Services | 1 | 2011 | 14 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 63 | 0.020 |
Why?
|
| Joints | 1 | 2011 | 43 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 718 | 0.020 |
Why?
|
| Quarantine | 1 | 2011 | 22 | 0.020 |
Why?
|
| Light | 1 | 2012 | 279 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 562 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 576 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2014 | 1015 | 0.020 |
Why?
|
| Poverty | 1 | 2014 | 476 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 597 | 0.020 |
Why?
|
| Moral Obligations | 1 | 2011 | 85 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 551 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2014 | 279 | 0.020 |
Why?
|
| Mice | 3 | 2009 | 35999 | 0.020 |
Why?
|
| Confidentiality | 1 | 2011 | 127 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 586 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 644 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2011 | 204 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 437 | 0.020 |
Why?
|
| Neuromuscular Agents | 1 | 2009 | 77 | 0.020 |
Why?
|
| Focus Groups | 1 | 2008 | 283 | 0.020 |
Why?
|
| Kidney | 1 | 2016 | 2339 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 1025 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2012 | 1005 | 0.020 |
Why?
|
| Breath Tests | 1 | 2006 | 201 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2004 | 14 | 0.020 |
Why?
|
| Polyethyleneimine | 1 | 2004 | 22 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 45 | 0.020 |
Why?
|
| CHO Cells | 1 | 2004 | 323 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 271 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2006 | 485 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 135 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 792 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 601 | 0.010 |
Why?
|
| Androgens | 1 | 2004 | 558 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 2088 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 3082 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 4360 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 1986 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 3076 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 7464 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 6661 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 14871 | 0.010 |
Why?
|